Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. SNGX, was recently a guest on Benzinga's All-Access.
Soligenix, a late-stage biopharmaceutical company, is focused on developing and commercializing treatments for rare diseases. The company’s key focus is on HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, and the expansion of synthetic hypericin into psoriasis and other inflammatory diseases.
Schaber shared exciting updates from the company's phase 3 study of HyBryte. Preliminary results are expected in mid 2026.
Watch the full interview here:
Featured photo by Online Marketing on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
